Analytical Data
-
Gene name
GCY1
- Application
-
Alternative Names
GCY1；GCY；Glycerol 2-dehydrogenase (NADP(+))
-
Species
E.coli
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14065
-
Expression Region
1-312aa
-
AA Sequence
MPATLHDSTKILSLNTGAQIPQIGLGTWQSKENDAYKAVLTALKDGYRHIDTAAIYRNEDQVGQAIKDSGVPREEIFVTTKLWCTQHHEPEVALDQSLKRLGLDYVDLYLMHWPARLDPAYIKNEDILSVPTKKDGSRAVDITNWNFIKTWELMQELPKTGKTKAVGVSNFSINNLKDLLASQGNKLTPAANQVEIHPLLPQDELINFCKSKGIVVEAYSPLGSTDAPLLKEPVILEIAKKNNVQPGHVVISWHVQRGYVVLPKSVNPDRIKTNRKIFTLSTEDFEAINNISKEKGEKRVVHPNWSPFEVFK
-
Molecular Weight
37.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GCY1, or guanylate cyclase Y1, is an enzyme that plays a crucial role in the conversion of GTP to cyclic GMP, a key second messenger involved in various physiological processes. Research into GCY1 has gained significance due to its implications in cardiovascular health, neuronal signaling, and cellular response to stress. Dysregulation of cyclic GMP pathways has been linked to numerous diseases, including heart failure, hypertension, and neurological disorders. As a result, GCY1 has become a target for drug development and therapeutic interventions aimed at modulating cyclic GMP levels. The recombinant expression of GCY1 allows for the production of large quantities of the enzyme, facilitating detailed studies into its structure, function, and interaction with other cellular components. Understanding the biochemical properties of GCY1 through recombinant protein studies can provide insights into its regulatory mechanisms and potential as a therapeutic target. Furthermore, advances in protein engineering techniques have opened new avenues for creating GCY1 variants with enhanced properties, promising breakthroughs in both basic research and clinical applications. Overall, the study of recombinant GCY1 protein is essential for elucidating the roles of cyclic GMP in health and disease, driving the development of innovative therapeutic strategies.
